CNS Portfolio Growth A diversified CNS portfolio enables cross-selling across neurology, movement disorders, psychiatry, and women's health, with approved therapies for ADHD, Parkinson's disease-related symptoms, epilepsy, migraine, cervical dystonia and chronic sialorrhea, and potential postpartum depression treatment via Zurzuvae. This creates opportunities for coordinated medical education, patient access programs, and payer strategies to grow prescriptions across multiple indications.

Strategic Acquisitions The CNS portfolio has expanded through acquisitions (US WorldMeds assets, Adamas, Sage) which broaden depth and add women's health capability. This provides opportunities to offer integrated CNS care pathways, pursue co-promotion or licensing deals, and leverage expanded distribution networks across neurology and obstetrics channels.

Financial Momentum Strong revenue trajectory in early 2026 and a sizable revenue base support scalable sales expansion, market access initiatives, and strategic partnerships. Opportunities include growing field teams, enhancing payer negotiations, and accelerating adoption of existing products and future indications or geographies.

Market Focus & Segments The portfolio targets ADHD, Parkinson's disease motor symptoms, epilepsy, migraine, cervical dystonia, and postpartum depression, enabling tailored sales plays for neurology clinics, movement disorder centers, epilepsy programs, psychiatry practices, and obstetrics networks. This supports bundled offerings and coordinated care pathways across the CNS portfolio.

Digital & Partnerships The company employs Salesforce Marketing Cloud and other digital platforms to support provider and patient outreach, with potential to scale digital engagement, analytics-driven targeting, and provider portals. These capabilities can drive partnerships for clinical trials, licensing, co-promotion, and payer collaborations to accelerate market access.